Turning point therapeutics, inc. (TPTX)
CashFlow / Yearly
Dec'19Dec'18Dec'17
Operating activities
Net loss

-72,131

-24,785

-16,593

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

12,706

1,147

344

Depreciation

492

138

63

Accretion of discount on marketable securities

1,357

-

-

Amortization of right-of-use operating lease asset

1,087

-

-

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

5,302

-88

179

Security deposits

-

-35

7

Accounts payable

903

-119

1,286

Accrued expenses and other current liabilities

522

-945

2,077

Accrued compensation

5,323

978

355

Net cash used in operating activities

-57,757

-23,533

-12,640

Investing activities
Purchases of marketable securities

432,173

-

-

Sales and maturities of marketable securities

72,838

-

-

Purchases of property and equipment

1,744

302

88

Net cash provided by (used in) investing activities

-361,079

-302

-88

Financing activities
Proceeds from issuance of common stock in initial public offering, net

175,151

-

-

Proceeds from issuance of common stock in public offering, net

189,505

-

-

Proceeds from issuance of convertible preferred stock, net of issuance costs

-

79,755

44,788

Proceeds from issuance of common stock

1,339

76

63

Net cash provided by (used in) financing activities

365,995

79,831

44,851

Net decrease in cash and cash equivalents

-52,841

55,996

32,123

Supplemental disclosure of cash flow information:
Cash paid for income taxes

1

1

1

Supplemental disclosure of non-cash investing and financing information:
Purchases of property and equipment in accounts payable

490

-

-

Costs incurred in connection with the initial public offering included in accounts payable and accrued expenses

-

684

-

Capitalized value of tenant improvement allowance

-

583

-

Operating lease liabilities arising from obtaining right-of-use assets

5,554

-

-